Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Antipsychotic Treatment”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT05654870
What this trial is testing

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

Who this might be right for
Schizophrenia
Neurocrine Biosciences 8
Post-approval studies (Phase 4)Not Yet RecruitingNCT07075237
What this trial is testing

Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia

Who this might be right for
Schizophrenia
Jiangsu Province Nanjing Brain Hospital 120
Post-approval studies (Phase 4)Ended earlyNCT00159757
What this trial is testing

12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients

Who this might be right for
Schizophrenia
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 150
Large-scale testing (Phase 3)Active Not RecruitingNCT00179465
What this trial is testing

Treating Schizophrenia by Correcting Abnormal Brain Development

Who this might be right for
Schizophrenia
Beth Israel Deaconess Medical Center 36
Large-scale testing (Phase 3)Study completedNCT03848234
What this trial is testing

Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder

Who this might be right for
SchizophreniaSchizoaffective DisorderSchizophreniform Disorders
Tangent Data 209
Large-scale testing (Phase 3)Study completedNCT00077727
What this trial is testing

The Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

Who this might be right for
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 107
Testing effectiveness (Phase 2)Study completedNCT01731119
What this trial is testing

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

Who this might be right for
SchizophreniaSchizoaffective DisorderSchizophreniform Disorder+10 more
University of North Carolina, Chapel Hill 9
Not applicableUnknownNCT04575103
What this trial is testing

Monitoring of Arrhythmias in Patients Treated With Antipsychotics

Who this might be right for
Death, Sudden, CardiacArrythmiaAntipsychotics and Neuroleptics Toxicity
Herlev and Gentofte Hospital 600
Large-scale testing (Phase 3)WithdrawnNCT00568672
What this trial is testing

Optimal Duration of Olanzapine Add-on Therapy in Major Depression

Who this might be right for
Relapse Rate of a Major Depressive EpisodeSafety of Olanzapine in Subjects With Major Depression
Charite University, Berlin, Germany
Large-scale testing (Phase 3)Study completedNCT01977300
What this trial is testing

Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

Who this might be right for
Bipolar I Disorder
University of British Columbia 159
Large-scale testing (Phase 3)Study completedNCT00253136
What this trial is testing

The Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia

Who this might be right for
SchizophreniaPsychotic Disorders
Janssen, LP 458
Post-approval studies (Phase 4)Active Not RecruitingNCT04892199
What this trial is testing

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

Who this might be right for
Metabolic DisturbanceSchizophreniaType 2 Diabetes+3 more
Anders Fink-Jensen, MD, DMSci 104